These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31106530)

  • 21. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
    Li T; Wang J
    BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Combination of TLR7 agonist T7-ethacrynic acid conjugate with ROR1 has a stronger anti-breast cancer effect].
    Zhang N; Jin G; Jin Z; Liu B; Peng B; Gao N; Hu Y; Tang L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Jul; 32(7):876-80. PubMed ID: 27363264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Functional investigation of chimeric antigen receptor T cells targeting LMP1 antigen].
    He HZ; Xing YY; Zhang Y; Xu YX; Tian Z; Xing HY; Tang KJ; Rao Q; Wang JX; Wang M
    Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):229-234. PubMed ID: 35405781
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effect of signal peptide optimized by site-directed mutagenesis on the function of chimeric antigen receptor T cells].
    Liu Y; Li F; Dai H; Zhou R; Wang M; Gan S; Xu Y
    Sheng Wu Gong Cheng Xue Bao; 2024 Feb; 40(2):573-584. PubMed ID: 38369842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [An experimental study of CD4 targeted chimeric antigen receptor modified T cell with anti-lymphoma activity].
    Chen GH; Huang HW; Wang Y; Liu HW; Xu LJ; Ma X; Xue SL; He XF; Wang Y; Gu B; Li CX; Qiu HY; Tang XW; Jin ZM; Miao M; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2018 Feb; 39(2):148-152. PubMed ID: 29562451
    [No Abstract]   [Full Text] [Related]  

  • 26. ROR1-targeting switchable CAR-T cells for cancer therapy.
    Peng H; Nerreter T; Mestermann K; Wachter J; Chang J; Hudecek M; Rader C
    Oncogene; 2022 Aug; 41(34):4104-4114. PubMed ID: 35859167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Developing ROR1 Targeting CAR-T Cells against Solid Tumors in Preclinical Studies.
    Lee BK; Wan Y; Chin ZL; Deng L; Deng M; Leung TM; Hua J; Zhang H
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Killing cervical cancer cells by specific chimeric antigen receptor-modified T cells.
    He Y; Li XM; Yin CH; Wu YM
    J Reprod Immunol; 2020 Jun; 139():103115. PubMed ID: 32199196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Construction of specific artificial antigen-presenting cells for in vitro activation of CD19 chimeric antigen receptor T cells].
    Peng YJ; Wu QY; Liu HY; Zhao J; Wei HF
    Nan Fang Yi Ke Da Xue Xue Bao; 2017 May; 37(5):581-587. PubMed ID: 28539278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.
    Hojjat-Farsangi M; Jeddi-Tehrani M; Daneshmanesh AH; Mozaffari F; Moshfegh A; Hansson L; Razavi SM; Sharifian RA; Rabbani H; Österborg A; Mellstedt H; Shokri F
    PLoS One; 2015; 10(11):e0142310. PubMed ID: 26562161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
    Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
    Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.
    Balakrishnan A; Goodpaster T; Randolph-Habecker J; Hoffstrom BG; Jalikis FG; Koch LK; Berger C; Kosasih PL; Rajan A; Sommermeyer D; Porter PL; Riddell SR
    Clin Cancer Res; 2017 Jun; 23(12):3061-3071. PubMed ID: 27852699
    [No Abstract]   [Full Text] [Related]  

  • 35. [Preliminary study of the fourth-generation CAR-T cells targeting CS1 in the treatment of refractory and recurrent multiple myeloma].
    Feng DD; Chen XH; Guo JJ; Wang KK; Zhang XM; Gao JM
    Zhonghua Zhong Liu Za Zhi; 2021 Jun; 43(6):657-665. PubMed ID: 34289557
    [No Abstract]   [Full Text] [Related]  

  • 36. [Research on the effect of PD-L1 overexpression on CLL-1 CAR-T anti-acute myeloid leukemia].
    Lin GQ; Zhang YM; Kang LQ; Yu L; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):829-835. PubMed ID: 33190440
    [No Abstract]   [Full Text] [Related]  

  • 37. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Construction of HER2-specific CAR-T cells and in vitro analysis of their activity to suppress tumor cell growth].
    Li Y; Yao S; Li Y; Xu M; Zhang H; Zhang C
    Sheng Wu Gong Cheng Xue Bao; 2018 May; 34(5):731-742. PubMed ID: 29893081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform.
    Rydzek J; Nerreter T; Peng H; Jutz S; Leitner J; Steinberger P; Einsele H; Rader C; Hudecek M
    Mol Ther; 2019 Feb; 27(2):287-299. PubMed ID: 30573301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Application of Chimeric Antigen Receptor-Modified NK Cells in Multiple Myeloma].
    Wei HP; Yang N; Gu ZY; Zhao SS; Wang FY; Luo L; Guan LX; Gao CJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):796-801. PubMed ID: 29950222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.